Patrick Hagen
Overview
Explore the profile of Patrick Hagen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hagen P, DSouza A
Blood Rev
. 2024 Aug;
68:101228.
PMID: 39179452
Immunoglobulin light chain (AL) amyloidosis is a malignant plasma cell dyscrasia causing multi-organ morbidity. High dose melphalan and autologous stem cell transplantation (ASCT) is a preferred consolidation approach and is...
2.
Hagen P, Norton J, Tsai S, Campo L, Lee M, Gomez K, et al.
Br J Haematol
. 2024 Jan;
204(4):1422-1428.
PMID: 38176404
The standard of care for fit, newly diagnosed multiple myeloma patients includes induction therapy followed by consolidative high-dose chemotherapy with melphalan and autologous stem cell transplant (AHSCT). Intensified preparative regimens,...
3.
Hodge A, Sheean P, OConnor P, Tyler K, Kerschner A, Williams A, et al.
Support Care Cancer
. 2022 Oct;
30(12):9771-9779.
PMID: 36287278
Purpose: Multiple myeloma (MM) is the second most common hematologic malignancy in the USA, with higher rates observed in older adults and African Americans (AA). Survivors experience fatigue, bone pain,...
4.
Dadrass F, Esmail F, Regmi A, Mudaliar K, Mirza K, Kini A, et al.
Clin Case Rep
. 2022 Aug;
10(8):e6009.
PMID: 35949412
Acute myeloid leukemia (AML) arises from clonal expansion of malignant hematopoietic precursor cells in the bone marrow. In rare instances, AML can recur with prominent extramedullary manifestations (i.e., leukemia cutis...
5.
Sellin M, Berg S, Hagen P, Zhang J
Transl Oncol
. 2022 Jun;
22:101448.
PMID: 35660848
Multiple myeloma (MM) treatment regimens have vastly improved since the introduction of immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies; however, MM is considered an incurable disease due to inevitable relapse...
6.
Hagen P, Zhang J, Barton K
Blood Cancer J
. 2022 May;
12(5):83.
PMID: 35637223
Multiple myeloma (MM) is an acquired malignant plasma cell disorder that develops late in life. Although progression free and overall survival has improved across all age, race, and ethnic groups,...
7.
Hagen P, Sellin M, Berg S, Zhang J
Ann Hematol
. 2022 May;
101(7):1407-1420.
PMID: 35585246
Our understanding of MM genomics has expanded rapidly in the past 5-10 years as a consequence of cytogenetic analyses obtained in routine clinical practice as well as the ability to...
8.
Berg S, Kim S, Wozniak A, Odetola O, Arain S, Aleem A, et al.
Am J Hematol
. 2022 Mar;
97(6):E217-E220.
PMID: 35303373
No abstract available.
9.
Pasvolsky O, Yeshurun M, Fraser R, Estrada-Merly N, Rozovski U, Shargian-Alon L, et al.
Bone Marrow Transplant
. 2021 Oct;
57(1):31-37.
PMID: 34608275
The role of maintenance therapy after high-dose chemotherapy and first autologous transplantation in multiple myeloma (MM) is well established. We explored the effect of maintenance therapy on outcomes after salvage...
10.
Hagen P, Hossain N
Transplant Cell Ther
. 2021 Mar;
27(2):192-193.
PMID: 33781546
No abstract available.